
    
      This is an open label (everyone knows the study intervention), Phase 2 study to evaluate
      efficacy and safety of daratumumab in relapsed or refractory mantle cell lymphoma, diffuse
      large B-cell lymphoma, and follicular lymphoma. The study will have three phases. Screening
      phase, treatment phase, follow-up phase. Participants will receive daratumumab (16 milligram
      per kilogram [mg/kg]) as intravenous infusion approximately 3.5 years. Participants will
      primarily be assessed for overall response rate. Safety will be monitored throughout the
      study.
    
  